Building on IMpower133, the CASPIAN trial demonstrated significant survival benefits with first-line chemoimmunotherapy, resulting in the approval of durvalumab(PD-L1 inhibitor) for ES-SCLC (6). Here, CD274 is linked to small cell lung carcinoma.